Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Based on results from the phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials the FDA has approved neoadjuvant and adjuvant trastuzumab deruxtecan for patients with HER2-positive early breast cancer.
Based on results from the phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials the FDA has approved neoadjuvant and adjuvant trastuzumab deruxtecan for patients with HER2-positive early breast cancer.
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib-based combinations in previously treated HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib-based combinations in previously treated HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
